Zhang et al. (44) found that MCH levels before treatment could serve as a predictive marker linked to disease-free survival (DFS) in breast cancer, as patients in the higher MCH group exhibited shorter DFS times than those in the lower MCH group. The gene discussed is PMCH; the disease is breast carcinoma.